Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
UPMC Enterprises serves as the innovation, commercialization, and venture capital division of UPMC. It develops and invests in digital health solutions, diagnostics, therapeutics—including gene therapies for retinal diseases and immunotherapies for cancer—and supports early-to-late stage growth companies. Its model has led to successful exits such as eVisit acquiring its teleconsult technology platform and Accuhealth merging with Signallamp. Recent clinical advances include progress at BlueSphere Bio, Cerevance, Mozart Therapeutics, Noema Pharma, SparingVision among others.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on UPMC Enterprises.